🇺🇸 FDA

Company profile · Sponsor

Beam

Beam Therapeutics

BEAM · NYSE biotech CAMBRIDGE, MA, USA
Pipeline
10
Drugs
3
Patents
8

Quick answer

Beam (BEAM) is a biotech company. headquartered in CAMBRIDGE, MA, USA. listed on NYSE. NovaPharmaNews links 10 pipeline programs, 3 drugs, and 8 patents to this profile..

Company facts

Ticker BEAM
Exchange NYSE
Company type biotech
Headquarters CAMBRIDGE, MA, USA
SEC CIK 0001745999

Pipeline (10)

Search pipeline →

  1. BEAM-101

    Beam

    Sickle Cell Disease

    phase 2 mab active

    1 trial

  2. BEAM-201

    Beam

    Lymphoblastic Lymphoma

    phase 2 mab active

    1 trial

  3. BEAM-301: Single dose of BEAM-301 administered by IV

    Beam

    Glycogen Storage Disease Type Ia

    phase 2 small molecule active

    1 trial

  4. BEAM-302

    Beam

    Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease

    phase 2 small molecule active

    1 trial

  5. BEAM-302

    Beam

    Alpha 1-Antitrypsin Deficiency

    phase 2 small molecule active

    1 trial

  6. Allogeneic anti-CD7 CAR-T cells (BEAM-201)

    Beam

    T-Cell Acute Lymphoblastic Leukemia/Lymphoma

    phase 1 mab active

    1 trial

  7. BEAM-103

    Beam

    Healthy Subjects

    phase 1 small molecule active

    1 trial

  8. BEAM Dream Powder

    Beam

    Sleep

    other completed

    1 trial

  9. Beam Organics Dream Powder

    Beam

    Sleep

    other completed

    1 trial

  10. PRDR

    Beam

    Glioma

    other active

    1 trial

Drugs (3)

Search drugs →

  1. cyproheptadine hydrochloride

    CYPROHEPTADINE HYDROCHLORIDE

    ORAL approved

  2. danazol

    DANOCRINE

    ORAL approved

  3. maprotiline hydrochloride

    MAPROTILINE HYDROCHLORIDE

    ORAL approved

Patents (8)

Search patents →

  1. US 12296053

    Nanomaterials comprising triols

    Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12268753

    Nanomaterials comprising a biodegradable feature

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12133884

    Methods of substituting pathogenic amino acids using programmable base editor systems

    Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12059477

    Nanomaterials

    Expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12016908

    Compositions and methods for treating hemoglobinopathies

    Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11795443

    Uses of adenosine base editors

    Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11752202

    Compositions and methods for treating hemoglobinopathies

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11594345

    Method for producing Ac-225 from Ra-226

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Beam?

Beam (BEAM) is a biotech company. headquartered in CAMBRIDGE, MA, USA. listed on NYSE. NovaPharmaNews links 10 pipeline programs, 3 drugs, and 8 patents to this profile..

What pipeline programs does Beam sponsor?

We track 10 ClinicalTrials.gov-linked programs for Beam, including BEAM-101 and 9 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Beam company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.